Close
American Drug Delivery & Formulation Summit
Xylem

Elligo Health Research Acquires Protenium Clinical Research; Now over 1 Million Patients Have Access to Research with Elligo

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Study Identifies Tiered Manufacturing in Global Pharmaceutical Markets

A new research project from the Johns Hopkins Bloomberg...

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merckโ€™s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merckโ€™s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.
- Advertisement -

Elligo Health Research, an integrated research organization, has acquired Protenium Clinical Research. Protenium, an established research group led by Robert Strzinek, Ph.D., D.O., conducts pharmaceutical studies in a broad range of therapeutic areas.

Dr. Strzinek has more than 15 years of clinical research experience and will now conduct research at his practice in partnership with Elligo. The acquisition brings the number of patients in Elligoโ€™s Research Ready network to more than one million. As part of Elligoโ€™s Goes Directยฎ approach, these patients will now have access to clinical research as a care option from their own trusted physician.

โ€œJoining Elligoโ€™s Dallasโ€“Fort Worth Community of Research will ensure that we continue to provide the best clinical research opportunities to our patients and help us expand research opportunities across the region,โ€ said Dr. Strzinek. โ€œOur partnership allows us to focus on patient care while benefiting from Elligoโ€™s research relationships and operational expertise.โ€

Dr. Strzinek has completed over 150 research studies and authored numerous journal articles covering several areas including endocrinology and womenโ€™s health. He and the Elligo team will continue to conduct research and support other community-based health care providers participating in research.

โ€œThe opportunity to leverage Dr. Strzinekโ€™s highly experienced practice and integrated clinical operation in our Research Ready network and Communities of Research furthers our mission to bring together and empower health organizations and improve clinical trial access and efficiency,โ€ said John Potthoff, Ph.D., CEO at Elligo. โ€œWe are delighted to welcome him, and his staff and patients to the Elligo family.โ€

About Elligo
Elligo Health Research, an integrated research organization, expands access to clinical research by bringing together health care data, community physicians and their patients. Only Elligoโ€™s Goes Directยฎ approach and IntElligo Research Stackโ„ข clinical technology โ€” a complete standards-based technology solution โ€” deliver better patients and improved real-time data through Elligoโ€™s network of Research Ready sites within its Communities of Research. Learn more at elligodirect.com.

World Pharma Today brings together the global pharmaceutical industry โ€” from R&D leaders and regulatory affairs professionals to manufacturers and distribution executives โ€” through trusted editorial, market intelligence, and digital engagement.

Our 2026 Media Pack offers integrated solutions to reach your audience:

  • Magazine & Digital Editions Showcase your brand within premium pharmaceutical industry coverage read by executives and decision - makers worldwide.
  • Industry Insights & Reports Align with data - driven analysis, trend reports, and regional roundups across the global pharmaceutical and life sciences value chain.
  • Brand Authority & Credibility Position your company as a thought leader through expert commentary, interviews, and special features.

Latest stories

Related stories

Study Identifies Tiered Manufacturing in Global Pharmaceutical Markets

A new research project from the Johns Hopkins Bloomberg...

Structural Pricing Pressure is Reshaping Pharma in 2026

In 2026, global pricing pressure in the pharmaceutical sector has shifted from a temporary, cyclical issue to a structural constraint. Explore how U.S. reforms, European reference pricing, and biosimilar competition are forcing companies to embed pricing risk into core strategy.

Merck Targets $70B Revenue in 2026 with Cidara Deal

Merckโ€™s roughly $9.2 billion acquisition of Cidara Therapeutics and its $70 billion revenue ambition mark a strategic pivot toward respiratory vaccines and antivirals. Explore how this deal reshapes Merckโ€™s portfolio and signals a broader industry shift toward targeted M&A to offset patent cliffs.

U.S. Drug Pricing Reset Becomes Real in 2026

In 2026, U.S. drug pricing finally moved from policy debate to P&L impact. The first set of Medicare โ€œmaximum fair pricesโ€ and Mostโ€‘Favouredโ€‘Nationโ€“style reference pricing are reshaping pharma margins and launch strategies.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป